Repligen (RGEN) EBIT (2010 - 2026)

Repligen (RGEN) has 17 years of EBIT data on file, last reported at $15.9 million in Q1 2026.

• On a quarterly basis, EBIT rose 142.32% year-over-year to $15.9 million in Q1 2026; TTM through Mar 2026 was $64.5 million, a 299.87% increase from a year earlier, with the FY2025 full-year figure at $55.2 million, up 257.11% from the prior year.
• EBIT for Q1 2026 stood at $15.9 million, down from $17.9 million in the prior quarter.
• Over the last five years, EBIT for RGEN reached as high as $63.2 million in Q2 2022 and fell as low as -$36.5 million in Q4 2024.
• Historically, EBIT has averaged $18.1 million across 5 years, with a median of $13.9 million in 2025.
• Across the five-year window, EBIT sank 469.71% in 2024 and soared 314.82% in 2025, its largest moves.
• Year by year, EBIT stood at $48.8 million in 2022, then plunged by 79.78% to $9.9 million in 2023, then sank by 469.71% to -$36.5 million in 2024, then soared by 148.95% to $17.9 million in 2025, then fell by 10.79% to $15.9 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were $15.9 million in Q1 2026, $17.9 million in Q4 2025, and $16.8 million in Q3 2025.